




RealRate

PHARMACEUTICAL 2018

Flexion Therapeutics Inc
Rank 129 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2018

Flexion Therapeutics Inc Rank 129 of 349

The relative strengths and weaknesses of Flexion Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Flexion Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 165% points. The greatest weakness of Flexion Therapeutics Inc is the variable Revenues, reducing the Economic Capital Ratio by 45% points.

The company's Economic Capital Ratio, given in the ranking table, is -88%, being 190% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	397,990
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	30,572
Liabilities, Non-Current	13,364
Other Assets	32,138
Other Compr. Net Income	-336
Other Expenses	4.0
Other Liabilities	137,107
Other Net Income	-7,800
Property and Equipment	11,189
Research and Development	51,231
Revenues	355
Selling, General and Administrative Expense	78,801

Output Variable	Value in 1000 USD
Assets	441,317
Liabilities	181,043
Expenses	130,036
Stockholders Equity	260,274
Net Income	-137,481
Comprehensive Net Income	-137,649
Economic Capital Ratio	-88%

